IBDEI0KE ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9001,0)
 ;;=K76.7^^69^616^9
 ;;^UTILITY(U,$J,358.3,9001,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9001,1,3,0)
 ;;=3^Hepatorenal Syndrome
 ;;^UTILITY(U,$J,358.3,9001,1,4,0)
 ;;=4^K76.7
 ;;^UTILITY(U,$J,358.3,9001,2)
 ;;=^56497
 ;;^UTILITY(U,$J,358.3,9002,0)
 ;;=N00.0^^69^617^8
 ;;^UTILITY(U,$J,358.3,9002,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9002,1,3,0)
 ;;=3^Acute nephritic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,9002,1,4,0)
 ;;=4^N00.0
 ;;^UTILITY(U,$J,358.3,9002,2)
 ;;=^5015491
 ;;^UTILITY(U,$J,358.3,9003,0)
 ;;=N00.1^^69^617^7
 ;;^UTILITY(U,$J,358.3,9003,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9003,1,3,0)
 ;;=3^Acute nephritic syndrome w/ focal and segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,9003,1,4,0)
 ;;=4^N00.1
 ;;^UTILITY(U,$J,358.3,9003,2)
 ;;=^5015492
 ;;^UTILITY(U,$J,358.3,9004,0)
 ;;=N00.2^^69^617^4
 ;;^UTILITY(U,$J,358.3,9004,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9004,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,9004,1,4,0)
 ;;=4^N00.2
 ;;^UTILITY(U,$J,358.3,9004,2)
 ;;=^5015493
 ;;^UTILITY(U,$J,358.3,9005,0)
 ;;=N00.3^^69^617^5
 ;;^UTILITY(U,$J,358.3,9005,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9005,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,9005,1,4,0)
 ;;=4^N00.3
 ;;^UTILITY(U,$J,358.3,9005,2)
 ;;=^5015494
 ;;^UTILITY(U,$J,358.3,9006,0)
 ;;=N00.4^^69^617^3
 ;;^UTILITY(U,$J,358.3,9006,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9006,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,9006,1,4,0)
 ;;=4^N00.4
 ;;^UTILITY(U,$J,358.3,9006,2)
 ;;=^5015495
 ;;^UTILITY(U,$J,358.3,9007,0)
 ;;=N00.5^^69^617^6
 ;;^UTILITY(U,$J,358.3,9007,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9007,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,9007,1,4,0)
 ;;=4^N00.5
 ;;^UTILITY(U,$J,358.3,9007,2)
 ;;=^5015496
 ;;^UTILITY(U,$J,358.3,9008,0)
 ;;=N00.6^^69^617^1
 ;;^UTILITY(U,$J,358.3,9008,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9008,1,3,0)
 ;;=3^Acute nephritic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,9008,1,4,0)
 ;;=4^N00.6
 ;;^UTILITY(U,$J,358.3,9008,2)
 ;;=^5015497
 ;;^UTILITY(U,$J,358.3,9009,0)
 ;;=N00.7^^69^617^2
 ;;^UTILITY(U,$J,358.3,9009,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9009,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,9009,1,4,0)
 ;;=4^N00.7
 ;;^UTILITY(U,$J,358.3,9009,2)
 ;;=^5015498
 ;;^UTILITY(U,$J,358.3,9010,0)
 ;;=N00.8^^69^617^9
 ;;^UTILITY(U,$J,358.3,9010,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9010,1,3,0)
 ;;=3^Acute nephritic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,9010,1,4,0)
 ;;=4^N00.8
 ;;^UTILITY(U,$J,358.3,9010,2)
 ;;=^5015499
 ;;^UTILITY(U,$J,358.3,9011,0)
 ;;=N00.9^^69^617^10
 ;;^UTILITY(U,$J,358.3,9011,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9011,1,3,0)
 ;;=3^Acute nephritic syndrome w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,9011,1,4,0)
 ;;=4^N00.9
 ;;^UTILITY(U,$J,358.3,9011,2)
 ;;=^5015500
 ;;^UTILITY(U,$J,358.3,9012,0)
 ;;=N01.0^^69^617^69
 ;;^UTILITY(U,$J,358.3,9012,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9012,1,3,0)
 ;;=3^Rapidly progr neph synd w/ minor glomerular abnlt
